SecBot

SecBot
NYSE· Pharmaceutical Preparations· Inc. X0· CIK 0000901832

AZN

ASTRAZENECA PLC
$156.86 ▼ -0.53%
Prev close $157.70
Market cap$250.4B
ConsensusStrong Buy
12-mo target$212.17 (+35.3%)
▲ Bullish
Analyst conviction 8/10
High Impact Filing (7/10) Biotech & Drug Discovery
Snapshot
The big-picture read on AZN right now — valuation, ownership and activity at a glance.
Market Cap
$250.4B
Cap Size
Mega Cap
Analyst Consensus
Strong Buy (80%)
Inst. Holders
3 funds
Inst. Value
$126.4M
Inst. Activity
2 buys / 2 sells
Insider Activity
$3.2K buy / $2.2M sell
Insider Net $
-$2.2M
Social Sentiment
60° Warm
SEC Reports
20
Price chart 30d -3.0%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 28, 2026 clinical_trial_readout
T-90d Trial Readout: Benralizumab (Phase 3)
Trial: A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first As
Sep 23, 2026 Event
CRESTOR
Supplemental Approval — Labeling — ROSUVASTATIN — TABLET — ORAL
Sep 17, 2026 Event
AstraZeneca Pharmaceuticals v. Weiser, et al
Court ruling (ca10) — Docket: 25-01466
Sep 15, 2026 SEC
AstraZeneca's Non-Executive Chair Michel Demaré purchased 2,500 ordinary shares at £121.21 per share on 14 September 202
6-K — Impact 2/10
Sep 14, 2026 SEC
AstraZeneca announced that the Phase III SERENA-4 trial of Etcamah (camizestrant) plus palbociclib in 1st-line advanced
6-K — Impact 5/10
Sep 9, 2026 SEC
AstraZeneca announced FDA accelerated approval of Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for 1st-
6-K — Impact 7/10
Sep 8, 2026 Insider
Sharma Mani was granted 1 shares
See Remarks @ $162.60 ($162.60)
Aug 8, 2026 Insider
Sharma Mani bought 20.233 shares
See Remarks @ $160.57 ($3.2K)
Analyst ratings buy % -5.9%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Strong Buy 80% rate it Buy or better · 35 analysts
Strong Buy 13 37% Buy 15 43% Hold 6 17% Sell 1 3% Strong Sell 0 0%
Recent analyst actions
DateFirmActionRatingFirm rating
Aug 24, 2026CICCINITIATEOutperform 55%
Monthly consensus history
PeriodStr. BuyBuyHoldSellStr. SellBuy %Distribution
Sep 1, 2026131561080%
Aug 1, 2026131651083%
Jul 1, 2026131642083%
Jun 1, 2026131642083%
May 1, 2026131742083%
Apr 1, 2026121752081%
Mar 1, 2026121651082%
Feb 1, 2026111841085%
Price targets
Where 11 covering analysts think AZN trades over the next 12 months.
$212.17 +35.3% upside Strong Buy
Current$156.86 Low$184.00 Median$215.00 High$240.00 11 analysts
$184.00$240.00
Analyst rating Strong Buy· 1.5/5 as of Oct 2, 2026
Social media sentiment mood -16.7%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
60°
Warm
BearishNeutralBullish
6 mentions 2 bullish 0 bearish 4 neutral
Recent posts
wallstreetbets Neutral 2mo ago
That 2030 guidance alone makes this worth watching. 33% higher and a $5B drug? Upgrades incoming. AZN has been sleeping too long.
▲ 1 · 💬 0· ⚡ 0.5
wallstreetbets Neutral 2mo ago
AstraZeneca $AZN
▲ 1 · 💬 0· ⚡ 0.5
wallstreetbets Bullish 2mo ago
$8000 call bet on AZN
▲ 1 · 💬 6· ⚡ 0.5
stocks Neutral 3mo ago
Is AstraZeneca ($AZN) a sleeping giant or a value trap?
▲ 1 · 💬 0· ⚡ 0.5
wallstreetbets Bullish 3mo ago
Bull case for AZN
▲ 1 · 💬 0· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
20 SEC filing reports analyzed · 7 bullish, 2 bearish, 0 mixed, 11 neutral · avg impact 4.1/10.
NEUTRAL6-K2/10
AstraZeneca's Non-Executive Chair Michel Demaré purchased 2,500 ordinary shares at £121.21 per share
Sep 15, 2026
BEARISH6-K5/10
AstraZeneca announced that the Phase III SERENA-4 trial of Etcamah (camizestrant) plus palbociclib i
Sep 14, 2026
BULLISH6-K7/10
AstraZeneca announced FDA accelerated approval of Etcamah (camizestrant) in combination with a CDK4/
Sep 9, 2026
BEARISHCOURT-RULING3/10
AstraZeneca's lawsuit challenging Colorado's 340B contract pharmacy protection law (S.B. 71) was dis
Sep 1, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 2, 2026
Clinical Trial
Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN
Phase Phase 2 — COMPLETED
Oct 2, 2026
Clinical Trial
A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity
Phase Phase 2 — COMPLETED
Oct 1, 2026
Clinical Trial
Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life
Phase Phase 3 — COMPLETED
Oct 1, 2026
Clinical Trial
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
Phase Phase 3 — COMPLETED
Sep 30, 2026
Clinical Trial
Dapagliflozin Versus Dexamethasone Role in Pre-operative Management of Non- Diabetic Brain Tumor Patients
Phase Phase 3 — COMPLETED
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
PeriodEPS Est.RangeGrowth30d RevUp/DnRevenue#
Current Q$0.00$0.00–$0.00———$16.1B—
Next Q$0.00$0.00–$0.00———$16.7B—
Current FY$10.09$10.03–$10.14120.2%+0.0%—$63.2B2
Next FY$11.58$11.38–$11.7814.8%+0.0%—$67.0B2
Institutional ownership
Which big funds own AZN (from quarterly 13F filings) and who is adding or trimming.
3 institutional holders with $126.4M total value (667,014 shares) as of 2026-Q2. Top holders: Mediolanum, FAYEZ, HUNTINGTON.
Top holders — 2026-Q2
FundSharesValue% TrackedLast move
Mediolanum International Funds Ltd487,420$92.3M73.1%NEW
FAYEZ SAROFIM & CO179,593$34.1M26.9%NEW
HUNTINGTON NATIONAL BANK1$93.000.0%NEAR_EXIT -100.0%
Recent position changes
FundActionPrevCurrentChangeValue
Mediolanum International Funds LtdNEW—487,420—$92.3M
FAYEZ SAROFIM & CONEW—179,593—$34.1M
CAPITAL FUND MANAGEMENT S.A.EXIT51,1610-100.0%$0.00
AXIOM INVESTORS LLC /DEEXIT62,7280-100.0%$0.00
AXIOM INVESTORS LLC /DENEW—62,728—$12.4M
CAPITAL FUND MANAGEMENT S.A.NEW—51,161—$10.1M
Corient Private Wealth LLCNEAR_EXIT208,74712,631-93.9%$2.4M
Gotham Asset Management, LLCTRIM4,1692,868-31.2%$565.6K
HUNTINGTON NATIONAL BANKNEAR_EXIT8,9561-100.0%$93.00
NORGES BANKEXIT1,276,1810-100.0%$0.00
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
1 insiders, 8 transactions. Net -$2.2M — $3.2K bought, $2.2M sold.
DateInsiderTitleTypeSharesPriceValue
Sep 8, 2026Sharma ManiSee RemarksAWARD1$162.60$162.60
Aug 8, 2026Sharma ManiSee RemarksBUY20.233$160.57$3.2K
Aug 6, 2026Sharma ManiSVP, Group ControllerAWARD2$163.34$326.68
Jul 6, 2026Sharma ManiSee RemarksAWARD2$190.43$380.86
Jun 8, 2026Sharma ManiSee RemarksAWARD1$179.75$179.75
May 20, 2026Sharma ManiSee RemarksSELL11,893$185.78$2.2M
May 6, 2026Sharma ManiSee RemarksAWARD1$186.28$186.28
Apr 7, 2026Sharma ManiSee RemarksAWARD1$196.03$196.03
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for AZN.
Shares short
2,087,754
Settlement Sep 15, 2026
Change vs prior
-27.9%
Semi-monthly cycle
Days to cover
1.0
At avg daily volume
Of shares outstanding
≈0.1%
Estimate — not % of float
All AZN filing & press-release reports (54)